Mutant KRAS vaccination for pancreatic cancer interception: the G12D immunogenicity paradox
In a recent study published in Cancer Discovery , Haldar and colleagues report the first-in-human evaluation of a pooled mutant (Kirsten rat sarcoma viral oncogene homolog) KRAS peptide vaccine in individuals at high risk of pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable mutant KRAS-specific T-cell responses in most participants, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops. 1
Authors
- Mie Linder Hübbe (ORCID: https://orcid.org/0000-0002-0202-5784)
- Morten Orebo Holmström (ORCID: https://orcid.org/0000-0002-3764-8578)
- Mads Hald Andersen (ORCID: https://orcid.org/0000-0002-2914-9605)
- Inna Markovna Chen (ORCID: https://orcid.org/0000-0003-2891-0762)
Institutions
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-11-08
- DOI
- https://doi.org/10.1038/s41392-026-03088-3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovationsfonden
- Gentofte Hospital
- Herlev Hospital